Clinical trials: Immune Checkpoint Inhibitors
Cervical Carcinoma, Chemoradiotherapy
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
This study is a single-center, single-arm, open-phase II clinical study, the main purpose of which is to evaluate the effectiveness and safety of camrelizumab combined with concurrent chemoradiotherapy for early and locally…
- Conditions
- Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1, Immunotherapy
- Trial name
- NCT05311566
- Testing
- Camrelizumab plus Concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Lei Li
Cancer
The Role of SNP rs2910164 in Patients Treated With Immune Checkpoint Inhibitors
The objective of this study is to investigate whether the SNP rs2910164 in the pre-miR-146a gene is associated with outcome and toxicity of immune checkpoint inhibitor therapy.
- Trial name
- NCT04038996
- Volunteers
- 179 people
- Sponsor
- University of Freiburg
Renal Cell Carcinoma, Renal Cancer
Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer
This is a multicenter, exploratory, prospective study to identify angiogenesis and immune-related biomarkers predictive of progression free survival in patients with metastatic or advanced renal cell carcinoma treated by a…
- Conditions
- Renal Cell Carcinoma, Renal Cancer, Renal Cancer Metastatic
- Trial name
- ANGIOCOR (NCT05285579)
- Testing
- Blood collection, Tumour samples
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Solid Tumor, Lymphoma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers.
- Trial name
- NCT03544723
- Testing
- Ad-p53
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MultiVir, Inc.
Immune Checkpoint Inhibitors, Lung Cancer
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
the purpose of this study is to identify multi-dimensional immunological biomarkers including cytokines, autoantibodies, and immune cell subtypes of immune-related adverse events (primary) and prognosis(secondary) in the…
- Trial name
- NCT05288569
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Esophageal Cancer
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
This clinical trial is designed to evaluate the preliminary efficacy and safety of an oncolytic virus combined with chemotherapy and an immune checkpoint inhibitor in patients with initially unresectable, locally advanced…
- Trial name
- NCT07061704
- Testing
- Oncolytic Virus: Administered via intratumoral injection (metastatic lesions in the neck or supraclavicular lymph nodes) once every 3 weeks, for a total of two to four doses., Oncolytic Virus: Administered via intratumoral injection (primary lesions) once every 3 weeks, for a total of two to four doses.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Esophageal Squamous Cell Carcinoma
Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
This is a prospective, single-center, single-arm Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with tislelizumab in patients with advanced esophageal squamous cell…
- Trial name
- NCT07811752
- Testing
- Sacituzumab Tirumotecan (SKB264) plus Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Shanghai Chest Hospital
Biliary Tract Neoplasms Immunotherapy
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
An investigation into the survival outcomes, progression-free survival, and safety of triple therapy with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib in patients with advanced HER2-positive/low-expressing biliary tract…
- Trial name
- NCT07704177
- Testing
- Trastuzumab Rezetecan, Adebrelimab, Lenvatinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Patient Reported Outcome Measures, Patient Safety
ePRO-based Model of Care to Manage and Monitoring Symptoms of Cancer Patients Treated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (IrAEs) throughout and beyond treatment duration. These IrAEs can be varied and difficult to predict, as they can involve almost any organ, regardless of…
- Trial name
- IePRO (NCT05530187)
- Testing
- Electronic Patient-reported Outcomes-based Model of Care
- Where
- 2 sites in Switzerland
- Volunteers
- 198 people
- Sponsor
- Manuela Eicher
Cancer
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
The goal of this clinical research study is to learn if ustekinumab can help to control immune-related diarrhea and/or colitis in cancer patients.
- Trial name
- NCT06807593
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic or Locally Advanced Unresectable Solid Tumors
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
This is an open-label, multicenter, clinical study conducted in multiple parts to establish the safety, tolerability, Pharmacokinetic/Pharmacodynamic (PK/PD) profile, maximum tolerated dose (MTD) combinations (if observed) and…
- Trial name
- NCT05396833
- Testing
- Tuvusertib, Lartesertib, Avelumab
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lung Cancer
Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors
This project adopts a prospective, multicenter, randomized controlled clinical study to investigate the treatment of TCM in postoperative patients with driver gene negative lung cancer, according to two phases of postoperative…
- Trial name
- NCT05834413
- Testing
- chemotherapy plus TCM 1&ICIs plusTCM2
- Where
- China
- Volunteers
- 367 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Genito-Urinary Neoplasm
Microbial Diversity Between Inflamed and Non-inflamed Skin of Patients With Immune Checkpoint Inhibitor-Induced Dermatitis
This study determines microbial diversity between inflamed and non-inflamed skin of patients with immune checkpoint inhibitor-induced dermatitis. Skin has millions of bacteria.
- Trial name
- NCT04812197
- Testing
- Biospecimen Collection(Punch Biopsy)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- City of Hope Medical Center
Locally Advanced or Metastatic NSCLC
PBF-1129 in Patients With NSCLC
Phase I clinical trial in Eastern Cooperative Oncology Group (ECOG) 0-1 patients with locally advanced or metastatic NSCLC to evaluate safety and tolerability of the compound PBF-1129, an Adenosine A2b receptor antagonist.
- Trial name
- NCT03274479
- Testing
- PBF-1129
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Palobiofarma SL
Malignant Solid Neoplasm
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or…
- Trial name
- NCT04871542
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- 849 sites in United States, Chile and 3 more
- Volunteers
- 2,062 people
- Sponsor
- SWOG Cancer Research Network
Non-small Cell Lung Cancer
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
This study was designed to evaluate the efficacy and safety of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) in combination with pemetrexed and anlotinib for treatment of elderly patients with T790M-negative advanced…
- Trial name
- NCT06277674
- Testing
- Cadonilimab plus Pemetrexed and Anlotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine